The Trump administration is ramping up its campaign to reduce soaring drug prices, with a series of initiatives and deadlines facing pharmaceutical companies. As the deadline approaches for drugmakers to lower prescription costs, companies are racing to implement changes amid increasing pressure. The administration is considering a new pricing policy, including the possibility of adopting the Most Favored Nation model to align U.S. drug prices with those in Europe. In a bid to enforce these changes, the administration has sent a proposed drug pricing rule to the White House for review, signaling a commitment to tackle high drug costs effectively. Industry leaders are on alert as the administration prepares to unveil significant policy updates, emphasizing the ongoing battle over affordable medication.